You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 24, 2024

Patent: RE39548


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE39548
Title:Interleukin-5 specific recombinant antibodies
Abstract: An effective anti-IL-5 recombinant antibody molecule comprising heavy and/or light chain antigen-binding residues from a donor antibody.
Inventor(s): Bodmer; Mark William (Cambridge, GB), Athwal; Diljeet Singh (London, GB), Emtage; John Spencer (Del Mar, CA)
Assignee: Celltech R&D Limited (Slough, Berkshire, GB)
Application Number:10/012,579
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent RE39548

Introduction

The United States Patent RE39548, though not specifically detailed in the provided sources, can be analyzed within the broader context of patent law, particularly focusing on the mechanisms of patent challenges, the role of Patent Assertion Entities (PAEs), and the standards for patentability. This analysis will delve into the key aspects of patent law relevant to any reissued patent, such as RE39548.

Patentability Requirements

To understand the validity and strength of any patent, including RE39548, it is crucial to examine the patentability requirements set forth by the U.S. Patent Act.

Eligible Subject Matter Requirement

The Patent Act allows patents on "any new and useful process, machine, manufacture, or composition of matter, or any improvement thereof"[1]. However, the Supreme Court has clarified that "laws of nature, natural phenomena, and abstract ideas" are not patentable. For a patent to be valid, it must pass the Alice/Mayo test, which ensures that the patent claims contain an "inventive concept" that transforms the nature of the claim into a patent-eligible application[1].

Novelty Requirement

The claimed invention must be novel, meaning it must not have been patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention[1].

Nonobviousness Requirement

Even if a claimed invention is novel, it must also be nonobvious. This means that the invention must not be obvious to a person having ordinary skill in the relevant art at the time of the invention[1].

Patent Challenges: Inter Partes Review (IPR) and Post-Grant Review (PGR)

The Leahy-Smith America Invents Act (AIA) introduced IPR and PGR as mechanisms to challenge the validity of patents.

Purpose and Benefits

Congress aimed to improve patent quality and provide a more efficient system for challenging patents that should not have issued. These proceedings are often faster, cheaper, and require a lower burden of proof compared to federal court litigation[1].

Process

IPR and PGR allow anyone to challenge patents before the USPTO. If successful, these proceedings can result in the cancellation of patent claims that the Patent Trial and Appeal Board (PTAB) concludes should not have been issued. This process typically must reach a final determination within one year after PTAB decides to institute the proceeding[1].

Role of Patent Assertion Entities (PAEs)

PAEs, often referred to as "patent trolls," play a significant role in the patent landscape.

Business Models

The FTC identified two distinct PAE business models: Portfolio PAEs and Litigation PAEs. Portfolio PAEs negotiate licenses covering large portfolios without necessarily suing the alleged infringer, while Litigation PAEs focus on suing for patent infringement before licensing. Litigation PAEs account for the majority of reported licenses but generate less revenue compared to Portfolio PAEs[4].

Impact on Patent Landscape

PAEs can significantly impact the patent landscape by asserting patents against a broad range of industries. This can lead to increased litigation and licensing costs for companies, particularly in the technology sector. The FTC study highlighted that PAEs often target firms in various industries, including retail trade, with a significant portion of their activity involving software-related patents[4].

Court Interpretations and Disputes

Court decisions play a crucial role in shaping the patent landscape.

Claim Construction and Infringement Allegations

In cases like Lite-Netics LLC v. Nu Tsai Capital LLC, the courts must interpret patent claims and determine whether infringement allegations are objectively baseless. The Federal Circuit has emphasized that claim terms must be given the meaning that the relevant artisan would understand, and that reasonable interpretations of patent claims should not be deemed objectively baseless without thorough analysis[2].

FRAND Determination and SEP Regulation

The European Commission's proposal for the regulation of Standard Essential Patents (SEPs) has faced criticism for its potential to infringe on fundamental rights and for its oversimplified approach to determining FRAND (Fair, Reasonable, and Non-Discriminatory) royalty rates. This highlights the complexities and controversies surrounding patent regulation and licensing practices[3].

Key Takeaways

  • Patentability Requirements: Patents must meet eligibility, novelty, and nonobviousness requirements to be valid.
  • IPR and PGR: These mechanisms provide efficient and cost-effective ways to challenge patent validity.
  • PAEs: They significantly impact the patent landscape through various business models, often targeting multiple industries.
  • Court Interpretations: Judicial decisions are critical in interpreting patent claims and resolving infringement disputes.
  • Regulatory Challenges: Proposals like the EC's SEP regulation face criticism for their potential impact on patent holders and implementers.

FAQs

What are the main requirements for a patent to be considered valid in the United States?

A patent must be directed to eligible subject matter, be novel, and be nonobvious to be considered valid.

How do IPR and PGR differ from federal court litigation?

IPR and PGR are generally faster, cheaper, and require a lower burden of proof compared to federal court litigation.

What are the two main business models of Patent Assertion Entities (PAEs)?

PAEs operate under two models: Portfolio PAEs, which negotiate licenses over large portfolios, and Litigation PAEs, which focus on suing for patent infringement.

Why is the European Commission's SEP regulation proposal controversial?

The proposal is criticized for restricting a patentee's court access during the FRAND determination procedure and for its oversimplified approach to determining FRAND royalty rates.

How do court interpretations impact patent disputes?

Court interpretations of patent claims and infringement allegations are crucial in resolving disputes and determining the validity of patents.

Sources

  1. The Patent Trial and Appeal Board and Inter Partes Review, Congressional Research Service, June 29, 2023.
  2. Lite-Netics LLC v. Nu Tsai Capital LLC, Federal Circuit, February 17, 2023.
  3. A Critical Analysis of the EC Proposal for SEP Regulation, Kluwer Patent Blog, February 27, 2024.
  4. Patent Assertion Entity Activity: An FTC Study, Federal Trade Commission, 2020.

More… ↓

⤷  Subscribe

Details for Patent RE39548

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Teva Respiratory, Llc CINQAIR reslizumab Injection 761033 March 23, 2016 ⤷  Subscribe 2014-06-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.